You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation.

This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.

Do you wish to leave this site?

Yes No

You are here


Canadian Advanced Parkinson Duodopa-Treated Patients Observational Study Evaluating Long-Term Health Outcomes in Centers of Excellence (Cadence)

    Status Recruiting
    Related Conditions
    Parkinson’s Disease

Enrollment Details

200 Worldwide Enrollment Goal


  • 1
  • 2
  • 3
  • 4
Study Type:  Observational

This is a type IV phase trial.

Protocol ID

Brief summary


The Cadence study will help us assess the impact of treatment with DUODOPA on Canadian patients with advanced Parkinson’s disease (PD).

Duodopa is the commercial name for a levodopa/carbidopa combination that comes in gel form. It is delivered inside the upper intestine via a small tube inserted directly into the first part of the small bowel, or duodenum. This unique delivery system – called intraduodenal infusion – uses a programmable pump to let the physician and patient individually tune the delivery of active ingredients, suspended as a stable gel, from a cassette worn outside the body.

Canada: 15

Lévis, QC
Montréal, QC
London, ON
Montréal, QC
Toronto, ON
Québec, QC
Vancouver, BC
Ottawa, ON
Hamilton , ON
Kingston, ON
Edmonton, AB
Sherbrooke, QC
Winnipeg, MB
Montréal, QC
Calgary, AB
Would you like to know more about this trial?

Study Design

  • The general design that describes the strategy for identifying and following up with participants during observational studies.

    Observational Model

    Open Label

  • The relationship between the observation period and the time of patient enrollment. Time perspective can be prospective: looking forward using periodic observations usually collected following patient enrollment, or retrospective: looking back using observations usually collected prior to patient selection and enrollment.

    Time Perspective


  • These are the major criteria to enter the study. Your study coordinator can explain any other contributing factors. Some of these medical terms may be difficult to understand – your study coordinator can clarify them for you.

    You can participate if you meet these criteria:

    • Adult > 18 years old.
    • Has provided a signed patient authorization allowing the use of their data for the study and providing permission for contact by the study personnel.
    • Diagnosed with advanced PD.
    • Prescribed Duodopa by his treating physician.

    You cannot participate if you meet these criteria:

    • Patient cannot or will not sign the patient authorization.
    • Patients who were previously treated with Duodopa.
    • Presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of advanced PD.